Pregnancy; concomitant administration with moderate or potent inhibitors of CYP3A4; moderately or seriously deteriorated liver (Child-Pugh class B or C) and patients suffering from active hepatic disorders, involving unjustified lasting increases of transaminases in the serum.

Hypersensitivity to lomitapide or other formula elements; identified critical, chronic disorders of the bowel such as malabsorption or inflammatory bowel disease; co-administration of daily simvastatin greater than 20 mg (co-administration with daily simvastatin of 40 mg daily is allowed for patients initially tolerant to daily simvastatin of 80 mg for a year or more with no indication of myotoxicity); intolerance to galactose, deficiency in Lapp-lactase, or malabsorption of glucose-galactose.